home / stock / arct / arct news


ARCT News and Press, Arcturus Therapeutics Ltd. From 11/10/20

Stock Information

Company Name: Arcturus Therapeutics Ltd.
Stock Symbol: ARCT
Market: NASDAQ
Website: arcturusrx.com

Menu

ARCT ARCT Quote ARCT Short ARCT News ARCT Articles ARCT Message Board
Get ARCT Alerts

News, Short Squeeze, Breakout and More Instantly...

ARCT - Why Arcturus Therapeutics Stock Soared Today

Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) were soaring 12.7% higher as of 3:28 p.m. EST on Tuesday. The big jump came after the clinical-stage biotech provided its third-quarter update following the market close on Monday. Investors were less interested in Arcturus' fi...

ARCT - Arcturus Therapeutics stock +6.1% despite Q3 miss

Arcturus Therapeutics ([[ARCT]] +6.0%) Q3 results:Collaboration revenue of $2.3M, compares with $3.3M last year, and misses consensus by $0.76M.Total operating expenses were $23.3M compares with $10.9M.Cash balance totaled $307.1M as of the end of Q3, compared to cash and cash equivalent...

ARCT - BP, ULTA, SAN and BNTX among premarket gainers

Greenland Technologies Holding (GTEC) +88% on launching integrated electric drivetrain.Trxade Group (MEDS) +70%.Summit Wireless Technologies (WISA) +42% on Q4 guidance.Mogo (MOGO) +27% on Q3 results.Fulgent Genetics (FLGT) +16% on Q3 results.Affime...

ARCT - Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2020 Results - Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2020 Results Earnings Conference Call November 09, 2020, 04:30 PM ET Company Participants Neda Safarzadeh - Head of Investor Relations, Public Relations & Marketing Joseph Payne - President & Chief Executive Officer Andy Sassine - Chief Fi...

ARCT - Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne On Q3 2020 Results - Quick Version Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2020 Earnings Conference Call November 09, 2020 4:20 PM ET Company Participants Neda Safarzadeh - Head of Investor Relations, Public Relations & Marketing Joseph Payne - President & Chief Executive Officer Steve Hughes - Chief Development ...

ARCT - Arcturus Therapeutics EPS misses by $0.44, misses on revenue

Arcturus Therapeutics (ARCT): Q3 GAAP EPS of -$0.92 misses by $0.44.Revenue of $2.3M (-30.7% Y/Y) misses by $0.76M.Shares +1.01%.Press Release For further details see: Arcturus Therapeutics EPS misses by $0.44, misses on revenue

ARCT - Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data

Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and si...

ARCT - BIIB, EPR, QDEL and AMC among midday movers

Gainers: Sundial Growers (SNDL) +79%.Aptevo Therapeutics (APVO) +60%.AMC Entertainment (AMC) +60%.Ashford Hospitality Trust (AHT) +58%.Cinemark Holdings (CNK) +56%.National CineMedia (NCMI) +48%.Tuniu (TOUR) +41%.EPR Properties (EPR) +41%.Dave & Buster's Entertainment (PLAY) +40%.Bro...

ARCT - Second tier COVID-19 vaccine developers under pressure on positive Pfizer/BioNTech data

Pfizer and BioNTech's announcement that, based on preliminary data, their COVID-19 vaccine is 90% effective and an emergency use authorization ((EUA)) is only weeks away has led to downward pressure on some of the second tier developers. If all goes according to plan, deployment could start b...

ARCT - Encouraging COVID-19 vaccine data fails to lift Arcturus, down 7%

The news that Pfizer and BioNTech's COVID-19 vaccine is 90% effective in preventing infection appears to be weighing on Arcturus Therapeutics Holdings (ARCT) despite positive preliminary results from a Phase 1/2 study assessing its candidate ARCT-021 in 106 young and old adult volunteers.78 s...

Previous 10 Next 10